Fig. 3
Effects of the inhibitors of arachidonic acid metabolism on 5-HT-induced coronary response in L-NAME-treated hearts. a Treatment with the PLA2 blocker quinacrine 1 μM slightly increased coronary flow, and after treatment of quinacrine, 5-HT-induced coronary flow increases were suppressed. b Treatment with the cytochrome P450 inhibitor SKF525A 3 μM significantly increased coronary flow, and in the presence of SKF525A, 5-HT-induced coronary flow increases were blocked. c Treatment of the COX inhibitor indomethacin 10 μM did not significantly influence 5-HT-induced coronary flow increase. Data were expressed as the mean ± SD. ***P < 0.005 compared to basal value; ###P < 0.005 compared to the treatment. ƗƗP < 0.01, ƗƗƗP < 0.005 compared to the control group (one-way ANOVA followed by Bonferroni post-test); &&P < 0.01 between the compared groups (2-ways ANOVA followed by Bonferroni post-test)